Daewoong Pharmaceutical is going to change partners in charge of the development and commercialization of Fexuprazan in the North American market. Daewoong Pharmaceutical announced on the 5th that it has terminated the exclusive license agreement with Neurogastrx of the United States for the clinical development and commercialization of Fexuprazan in the US and Canada markets under an agreement between the two companies. The two companies signed a contract in June 2021.

Daewoong Pharmaceutical explained that it decided to terminate the contract under the judgment that it needed a strategic partner that can quickly develop Fexuprazan for various indications in the North American market. Neurogastrx is sa